Strategic partnerships SphingoTec is actively partnering with Boditech Med to co-host a scientific symposium and collaborate on sepsis diagnostics, presenting a clear channel for co-marketing, bundled solutions, and joint BD opportunities in critical care biomarker testing.

Clinical adoption The company focuses on translating novel biomarkers into routine clinical practice for acute kidney injury, sepsis, and acute heart failure, signaling potential upsell of AFIAS penKid and related assays to hospitals and ICU networks seeking rapid, actionable diagnostic data.

Regulatory and events Participation in ESICM Lives and scientific symposiums with partners provides opportunities to engage key clinicians, drive awareness, and generate pilot programs or trial orders with critical care departments amid a growing sepsis diagnostics market.

Financing momentum Recent Series C funding and continued investment from multiple VCs indicate strong investor confidence and potential for scaling sales efforts, distribution expansion, and larger hospital system deals across regions.

Global reach potential With a global partner network and launches in Korea and Europe, there is a path to expand distribution of AFIAS sphingotest devices and penKid assays through non-dilutive partnerships, CROs, and distributor agreements to accelerate market penetration.